

Commission, telephone 202-205-3104. General information concerning the Commission may also be obtained by accessing its Internet server (<http://www.usitc.gov>). Hearing-impaired persons are advised that information on the matter can be obtained by contacting the Commission's TDD terminal on 202-205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on June 4, 1998, based on a complaint filed by Mitsubishi Chemical Corporation of Japan and Mitsubishi Chemical America, Inc., of White Plains New York (collectively, Mitsubishi). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, and the sale within the United States after importation of certain organic photoconductor drums and products containing same, by reason of infringement of two U.S. patents held by Mitsubishi.

On July 14, 1998, Mitsubishi and respondent Sinonar Corporation filed a joint motion under Commission rule 210.21(a) to terminate the investigation as to Sinonar based on Mitsubishi's withdrawal of the allegations in its complaint as to Sinonar. Upon examining documents and information provided by Sinonar, Mitsubishi concluded that Sinonar did not infringe its patents. On July 20, 1998, Mitsubishi and respondents Fuji Denki, Fuji Electric Co., Ltd, and U.S. Fuji Electric Inc. (collectively, Fuji) filed a similar joint motion to terminate the investigation as to the Fuji respondents. Upon examining documents and information provided by Fuji, Mitsubishi concluded that Fuji did not infringe the asserted patents. The Commission investigative attorney did not oppose either motion.

On August 21, 1998, The ALJ issued an ID (Order No. 6) granting the joint motion to terminate the investigation as to Sinonar. On the same date, he issued an ID (Order No. 7) terminating the investigation as to Fuji. No petitions for review were filed.

This action is taken under the authority of section 337 of the Tariff Act of 1930, 19 U.S.C. § 1337, and Commission rule 210.42, 19 CFR § 210.42.

Copies of the public version of the ALJ's ID, and all other nonconfidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone 202-205-2000.

By order of the Commission.

Issued: September 10, 1998.

Donna R. Koehnke,

Secretary.

[FR Doc. 98-24821 Filed 9-15-98; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Inv. No. 337-TA-408]

Certain Recombinantly Produced Hepatitis B Vaccines and Products Containing Same; Notice of Commission Determination Not To Review an Initial Determination Terminating the Investigation on the Basis of a Settlement Agreement

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge's (ALJ's) initial determination (ID) (Order No. 7) in the above-captioned investigation terminating the investigation on the basis of a settlement agreement.

FOR FURTHER INFORMATION CONTACT: Jean Jackson, Esq., Office of the General Counsel, U.S. International Trade Commission, telephone 202-205-3104. General information concerning the Commission may also be obtained by accessing its Internet server (<http://www.usitc.gov>). Hearing-impaired persons are advised that information on the matter can be obtained by contacting the Commission's TDD terminal on 202-205-1810.

SUPPLEMENTARY INFORMATION: This patent-based section 337 investigation was instituted by the Commission on

May 11, 1998, on behalf of complainant Chiron Corporation (Chiron) of Emeryville, California. 63 FR 25869. The complaint alleged violations of section 337 of the Tariff Act of 1930 in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain recombinantly produced hepatitis B vaccines that allegedly are covered by claims 4, 5, 7, or 8 of U.S. Letters Patent Re 35,749. The notice of investigation named SmithKline Beecham Biologicals, S.A. of Belgium and SmithKline Beecham Corporation of Philadelphia, Pennsylvania (collectively, "SKB") as respondents.

On August 7, 1998, complainant and respondents to the investigation filed a joint motion to terminate the investigation as to all issues based upon a settlement agreement, which was supported by the Commission investigative attorney. On August 18, 1998, the presiding ALJ granted the joint motion and issued an ID (Order No. 7) terminating the investigation on the basis of the settlement agreement. The ALJ found no indication that termination of the investigation would have an adverse impact on the public interest and that termination based on settlement is generally in the public interest. No petitions for review were filed.

This action is taken under the authority of section 337 of the Tariff Act of 1930, 19 U.S.C. 1337, and Commission rule 210.42, 19 CFR 210.42.

Copies of the public version of the ALJ's ID, and all other nonconfidential documents filed in connection with this investigation, are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone 202-205-2000.

By order of the Commission.

Issued: September 10, 1998.

Donna R. Koehnke,

Secretary.

[FR Doc. 98-24822 Filed 9-15-98; 8:45 am]

BILLING CODE 7020-02-P